Ipsogen sales and marketing update

Ipsogen launched its MapQuant Dx HR test in Europe to measure endocrine responsiveness of breast cancer tumors. The test runs on a microarray platform from Affymetrix Inc. (NASDAQ:AFFX, Santa Clara, ...